NCT02659358View on ClinicalTrials.gov

Evaluating the Use of Wearable Biosensors and PROs to Assess Performance Status in Patients With Cancer

CompletedOBSERVATIONAL
Enrollment

37

Participants

Timeline

Start Date

January 24, 2016

Primary Completion Date

August 24, 2017

Study Completion Date

August 24, 2017

Conditions
Neoplasms
Interventions
DEVICE

Fitbit Charge HR®

A wrist worn biosensor, the Fitbit Charge HR® has sensor capability, good battery life, water resistant, Bluetooth capabilities, and provides accessible data.

Trial Locations (1)

90048

Cedars-Sinai Medical Center, Los Angeles

All Listed Sponsors
lead

Cedars-Sinai Medical Center

OTHER

NCT02659358 - Evaluating the Use of Wearable Biosensors and PROs to Assess Performance Status in Patients With Cancer | Biotech Hunter | Biotech Hunter